Atherosclerosis Market Analysis

Growing incidence of heart attacks due to atherosclerosis or coronary heart disease is expected to increase demand for atherosclerosis treatment products. The rise in the aging population is expected to propel demand over the forecast period. As per CDC (Centers for Disease Control and Prevention), coronary illness accounts for around 610,000 deaths per year in the United States- roughly being responsible for 1 of every 4 deaths reported. Coronary illness is the most widely recognized kind of coronary illness, killing more than 370,000 individuals every year. This increase in the baby boomer population is expected to add to the patient pool of atherosclerosis and thus in turn increase demand for treatment over the forecast period. The development in atherosclerosis market is determined by expanded prevalence, obesity, sedentary lifestyle, hypertension, dyslipidemia, an especially decrease in high thickness cholesterol (HDL-C), and elevated cholesterol slim down. Medications to treat Atherosclerosis incorporates statins, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers (BB), antiplatelets, calcium channel blockers (CCBs) and nitrates. With the dispatch of first-in-class pipeline molecules, for example, Yosprala (headache medicine and omeprazole), Praluent (alirocumab), Dalcetrapib (RG1658), Vorapaxar (SCH 530348), Canakinumab (ACZ885), Varespladib (A 002), Aliskiren, Generx, Xarelto (rivaroxaban), Anacetrapib (MK0859), and others are relied upon to get propelled in the forecasting period. New contestants in the atherosclerosis market have indicated expanded adequacy and security profiles along with the reduction of CHD risk factors. Atherosclerosis or coronary artery disease showcase likewise has two different methods of treatment, which are coronary artery bypass grafting (CABG) and angioplasty. The CAD death rate is very high contrasted with different maladies because of coronary events connected with CAD, including myocardial infections (MI), angina and strokes. In this way, the counteractive action of such events remains an undiscovered region of research and development for pharmaceutical organizations to bring novel medications into the market. However, the absence of definitive treatment, side effects and limited efficacy of the drugs available in the market and dependency in symptom based treatment in several cases is expected to hamper revenue growth of the atherosclerosis market over the forecast period.

By Therapy

• Medications
  
  • Cholesterol-lowering medications
    
  • Antiplatelet drugs and anticoagulants
    
  • Beta blockers
    
  • Diuretics, or water pills
    
  • Angiotensin converting enzyme (ace) inhibitors
    
  • Others
    

By Surgery

• Bypass surgery (Coronary Artery Bypass Grafting (CABG))
  
• Angioplasty
  
• Atherectomy
  

By Distribution Channel

• Hospital Pharmacies
  
• Drug Stores
  
• Retail Pharmacies
  
• Clinics
  

The global market for atherosclerosis is expected to witness robust growth owing to increasing incidence rate of the heart problems coupled with new treatment (branded and generic) approach.

Globally the atherosclerosis market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America and Western Europe are expected to be the leading markets in the global atherosclerosis market. Rising treatment options among the aging population, prescription rates, and the maturing worldwide population are additionally considered vital drivers for this market. High awareness and easy available diagnostic tests are expected to boost demand for RSV infection treatment products in these regions. Japan and APEJ are expected to follow next in terms of demand for the treatment of atherosclerosis market. Eastern Europe, Latin America, and MEA markets are also expected to witness above average growth over the forecast period. The absence of population-based studies in developing countries is a major challenge in the assessment of RSV-related infections in these countries.

The report covers exhaustive analysis on:

• Market Segments
  
• Market Dynamics
  
• Market Size
  
• Current Trends/Issues/Challenges
  
• Competition & Companies involved
  
• Value Chain
  

Regional analysis includes:

• North America (U.S., Canada)
  
• Latin America (Mexico. Brazil)
  
• Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
  
• Eastern Europe (Poland, Russia)
  
• APEJ (China, India, ASEAN, Australia & New Zealand)
  
• Japan
  
• The Middle East and Africa (GCC, S. Africa, N. Africa)
  

Report Highlights:

• Detailed overview of parent market
  
• Changing market dynamics in the industry
  
• In-depth market segmentation
  
• Historical, current and projected market size in terms of volume and value
  
• Recent industry trends and developments
  
• Competitive landscape
  
• Strategies of key players and products offered
  
• Potential and niche segments, geographical regions exhibiting promising growth
  
• A neutral perspective on market performance
  
• Must-have information for market players to sustain and enhance their market footprint.